TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01843205

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
Study: NCT03682055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK-2019
Description: EBNA1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK-2019
Description: EBNA1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK-2019
Description: EBNA1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK-2019
Description: EBNA1 inhibitor
Study: NCT01067313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer Ultraflux EMiC2
Description: Dialysate flow rate = 40 ml/kg/h The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dialyzer Ultraflux AV1000S
Description: Ultrafiltration flow rate = 40 ml/kg/h The blood flow rate will be adjusted to obtain a filtration fraction of 20%. Reinjection = 100% postdilution. The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
Study: NCT02816476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Study: NCT02811172

Intervention type: OTHER
Intervention: BEhavior of biomarkers during pregnanCy and lactatiOn

Intervention type: OTHER
Intervention: BEhavior of biomarkers during pregnanCy and lactatiOn
Study: NCT03723408

Intervention type: DEVICE
Group type: OTHER
Intervention: ClearLine IV (formerly, AirPurge)
Description: Patient safety device that automatically and continuously detects and actively removes air from IV lines - protecting patients from dangerous air burden, air embolism, air infusions.
Study: NCT03064165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: Nerve block with 15 mL bupivacain 5 mg/mL with epinephrine 5 µg/mL.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham block
Description: Injection as for obturator nerve block, but with placebo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Obturator nerve block
Description: Postoperative obturator nerve block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: Placebo
Study: NCT02245230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin (1-7)
Description: Angiotensin (1-7) is a peptide produced by the body. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 20 ng/kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin (1-7)
Description: Angiotensin (1-7) is a peptide produced by the body. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 20 ng/kg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine is an alpha 1-adrenergic agonist. It will be administered as an acute intravenous infusion to restore blood pressure following trimethaphan with doses ranging from 0.1 to 0.5 ug/kg/min.
Study: NCT02867384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: B cell depletion

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02839811

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate hypersensitivity to BLC
Description: immediate hypersensitivity to BLC by In vitro diagnosis
Study: NCT03386006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Coach for Bariatric Health
Description: Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks.
Study: NCT02193854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Phone
Description: Investigators used Sana system, that is a mobile phone-based, open source software platform for telemedicine services. The Android-based system supports multimedia, location-based data, and text. In the village health clinic, a healthcare worker will interact with a patient and collects data through a step-by-step clinical questionnaire on a smart mobile phone. As patients' data is uploaded to an open source electronic medical record system (OpenMRS) with a diagnosis-specific information and images. The consultant can access the clinical information about the patient and make appropriate diagnoses and treatment recommendations from the secondary hospital.
Study: NCT02256527

Intervention type: OTHER
Intervention: Observational
Description: compare data
Study: NCT02912169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction under local anesthesia
Description: Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of AD-SVF via IV and Intranasal
Description: IV and Intranasal Infusion of isolated AD-SVF
Study: NCT04405843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Oral Product
Description: Ivermectin oral suspension, 6 mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
Study: NCT02398630

Intervention type: RADIATION
Group type: OTHER
Intervention: TC Virtual Hysterosalpingography
Description: Virtual hysterosalpingography: a new multidetector CT technique for evaluating the female reproductive system
Study: NCT03082807

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NCDsport
Description: Negative Calorie Diet supplemented with exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LCDsport
Description: Low-Calorie diet with exercise
Study: NCT02204410

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADHD Medication
Study: NCT00728663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8~--- for max. 24 weeks or until progression or unacceptable toxicity ---

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---
Study: NCT03708757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric relaxation - Group I
Description: Post isometric relaxation (PIR) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Muscle contraction - Group II
Description: and Eccentric muscle energy techniques(EME) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
Study: NCT02264015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine, low, film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine, high, film-coated tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, film-coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin, film-coated tablets
Study: NCT02736396

Intervention type: OTHER
Intervention: fMRI
Description: Functional MRI scan to be performed

Intervention type: OTHER
Intervention: fMRI
Description: Functional MRI scan to be performed
Study: NCT02398630

Intervention type: OTHER
Group type: OTHER
Intervention: MRI Virtual Hysterosalpingography
Description: Magnetic Resonance Imaging Virtual hysterosalpingography
Study: NCT02736396

Intervention type: OTHER
Intervention: Neuropsychological tests
Description: Cognitive assessments will be performed, including Mini Mental State Examination, Rey Auditory Verbal Learning Test, Stroop, Visual Short Term Memory Assessment.

Intervention type: OTHER
Intervention: Neuropsychological tests
Description: Cognitive assessments will be performed, including Mini Mental State Examination, Rey Auditory Verbal Learning Test, Stroop, Visual Short Term Memory Assessment.
Study: NCT01487707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary Health Worker (VHW) Program
Description: Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary Health Worker (VHW) Program
Description: Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary Health Worker (VHW) Program
Description: Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Birth Kit
Description: A safe birth kit, containing sterile materials to diminish infection risk will be given to pregnant women.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Folk Media Campaigns
Description: Community-wide media activities, including dramas, intended to address community norms regarding maternal and child health.
Study: NCT03275415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD
Study: NCT03048357

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Freedom Bed
Description: Fully Integrated Lateral Rotation Bed System that automatically turns the patient to a specific angle in degrees between from 15-25 with dwell times between 1-120 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard hospital bed
Description: Caregiver turning patients to one side then the other every 2 hours for pressure relief over bony prominence's.
Study: NCT02463318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin is used for healthy subjects and multiple sclerosis patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin is used for healthy subjects and multiple sclerosis patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide
Description: Hydrogen peroxide is only used for healthy subjects
Study: NCT02444936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZOSTAVAX
Description: Shingles vaccine
Study: NCT04538261

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fetal Pillow insertion
Description: Inflation of balloon device used to elevate fetal buttocks prior to performing external cephalic version procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal Pillow insertion
Description: Inflation of balloon device used to elevate fetal buttocks prior to performing external cephalic version procedure
Study: NCT03537092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Film
Description: 2 x 2 vaginal film with no active drug
Study: NCT04479007

Intervention type: DEVICE
Intervention: Probe based optical techniques
Description: During the intervention of inspecting the airways, different segments of the alveolar compartment will be imaged by two different probe based (CLE and OCT).
Study: NCT00261794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-assisted cognitive remediation (CACR)
Description: 36 individual computer sessions with a staff clinician. computer activities consist of commercially available educational software designed for use in the classroom.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: manualized computer control condition (RC).
Description: 36 sessions of a manualized computer control condition.
Study: NCT02398630

Intervention type: OTHER
Group type: OTHER
Intervention: Antimullerian Hormone dosing
Description: Blood Draw for Antimullerian Hormone dosing

Intervention type: OTHER
Group type: OTHER
Intervention: Transvaginal Echography
Description: Transvaginal Echography for evaluating the female reproductive system
Study: NCT01351389

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Intervention (BMI)
Description: The BMI incorporates open-ended exploration, personalized feedback, and discussion about patients' alcohol use and sexual behaviors and the consequences of these behaviors. Using the central principles described by Miller and Rollnick (2002), the goal of the session, conducted in the hospital as soon as possible, is to explore the patient's alcohol use and sexual behaviors and to help patients consider what they might want to change. Also included is a presentation of personalized feedback, and for patients who are interested in change, a focus on establishing goals for reduced drinking and sexual risk abstinence. Collaboratively the counselor and patient develop a plan for the future, identify goals for behavior change, explore barriers to changes, and provide strategic advice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice
Description: Patients in the Brief Advice (BA) condition will receive intervention consistent with standard medical practice when alcohol problems or sex-risk behaviors are indicated. Project staff will offer BA about level of alcohol/drug and sexual behaviors and drug problems risk, and will provide a list of treatment resources (including options for HIV testing) in the local area. Patients will be told they show signs of risk associated with alcohol use in that they scored above a cut-score for our alcohol screen, and that they reported recently engaging in sexually risky behaviors. The staff person will advise patients that reducing their alcohol use, and illicit drug use when relevant, and using condoms is advised. BA will take approximately 5 minutes.
Study: NCT00381589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipratropium bromide 0.03% spray
Study: NCT01594346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Tocopherol
Description: 1,000 International Units, two times a day for 36 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Study: NCT02136550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Smoking cessation is a program that gives all the support to the subject: orientation, medications, exams, etc
Study: NCT03835988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geniculate Artery Embolization
Description: Embolization is a procedure completed by an Interventional Radiologist in which abnormal blood vessels are blocked for treatment purposes. In the case of geniculate artery embolization, abnormal blood vessels which supply your knee joint are blocked in an effort to reduce inflammation and subsequently and reduce pain and improve joint function.
Study: NCT00453323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine 900mg/m2 bid po on day 1\~14, 1 weeks rest, until disease progression
Study: NCT00858676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acarbose
Description: 50mg acarbose 3 times a day PO. duration: one year
Study: NCT01496989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-MAG (3,000mcg)
Description: Delivered intramuscularly by in vivo electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-MAG (3,000mcg)
Description: Delivered intramuscularly by in vivo electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-MAG (3,000mcg)
Description: Delivered intramuscularly by in vivo electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-MAG (3,000mcg)
Description: Delivered intramuscularly by in vivo electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-MAG (3,000mcg)
Description: Delivered intramuscularly by in vivo electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GENEVAX® IL-12 (100mcg)
Description: Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GENEVAX® IL-12 (1000mcg)
Description: Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GENEVAX® IL-12 (1000mcg)
Description: Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GENEVAX® IL-12 (1000mcg)
Description: Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN/ENV
Description: (2x10\^10vp) Delivered intramuscularly by standard needle injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN/ENV
Description: (2x10\^10vp) Delivered intramuscularly by standard needle injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN/ENV
Description: (2x10\^10vp) Delivered intramuscularly by standard needle injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN/ENV
Description: (2x10\^10vp) Delivered intramuscularly by standard needle injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN/ENV
Description: (2x10\^10vp) Delivered intramuscularly by standard needle injection
Study: NCT01789892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV
Study: NCT02099682

Intervention type: DRUG
Intervention: Lansoprazole
Description: Lansoprazole Capsules 15/ OD Tablets
Study: NCT02548130

Intervention type: OTHER
Intervention: MELD score
Description: introduction of MELD score
Study: NCT02048930

Intervention type: DEVICE
Intervention: Budesonide Easyhaler

Intervention type: DEVICE
Intervention: Budesonide Easyhaler

Intervention type: DEVICE
Intervention: Budesonide Easyhaler

Intervention type: DEVICE
Intervention: Budesonide dry powder inhaler

Intervention type: DEVICE
Intervention: Budesonide dry powder inhaler

Intervention type: DEVICE
Intervention: Budesonide dry powder inhaler
Study: NCT00442039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: The starting dose of lithium was 300 mg for patients weighing \< 20 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability. The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability.
Study: NCT01789892

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FDG PET/CT scan
Study: NCT03245710

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: starch

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zhibai Dihuang powder
Description: the Traditional Chinese Medicine Formula Powder Product
Study: NCT01470365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo 3-dimensional CRT
Study: NCT03955497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-derived Mesenchymal Stem Cell Gel
Description: The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Hyaluronate
Description: The control group received intra-articular injection of sodium hyaluronate one month after operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of abdominal fat
Description: In the experimental group, abdominal fat was extracted before operation to prepare Autologous Adipose-derived Mesenchymal Stem Cell Gel.
Study: NCT03185468

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: 4SCAR-PSMA
Description: PSMA-specific 4th Generation CART

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: 4SCAR-FRa
Description: FRa-specific 4th Generation CART